中国65岁及以上成年人肺炎球菌疫苗的成本效果:比较研究
该研究采用决策树马尔可夫模型、从社会视角评估中国≥65岁老年人接种PPSV23、PCV13及PCV13-PPSV23序贯策略相对于不接种的成本效果。基础分析中三者的ICER分别为US$10,776.7/QALY、$9,193.2/QALY和$15,080.0/QALY。PCV13最具成本效果,且是唯一基于一次全国人均GDP阈值的成本效果策略。
要点
- PCV13的ICER为US$9,193.2/QALY,低于PPSV23的US$10,776.7/QALY和序贯策略的US$15,080.0/QALY。
- PCV13是唯一基于一次全国人均GDP阈值具成本效果的策略。
- PPSV23成本最低,PCV13-PPSV23序贯策略对肺炎球菌疾病负担影响最大。
核心结论
- 对中国老年人而言,PCV13接种比PPSV23接种和PCV13-PPSV23序贯接种更具成本效果。
研究设计与样本
- 采用决策树马尔可夫模型、从社会视角评估中国≥65岁老年人接种PPSV23、PCV13及PCV13-PPSV23序贯策略相对于不接种的成本效果。
- 参数包括流行病学数据、疫苗效力和成本数据来自既往研究。
主要发现
- 基础分析中,与不接种肺炎球菌疫苗相比,PPSV23、PCV13和PCV13-PPSV23的ICER分别为US$10,776.7/QALY、$9,193.2/QALY和$15,080.0/QALY。
- PCV13是最具成本效果的策略,且是唯一基于一次全国人均GDP阈值的成本效果策略。
- PPSV23疫苗策略成本最低,PCV13-PPSV23序贯策略对肺炎球菌疾病负担影响最大。
- 敏感性分析显示结果受血清型覆盖、疫苗效力、社区获得性肺炎发病率和疫苗价格影响较大。
关键数值与推荐
- PPSV23的ICER为US$10,776.7/QALY。
- PCV13的ICER为US$9,193.2/QALY。
- PCV13-PPSV23序贯策略的ICER为US$15,080.0/QALY。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to assess the cost-effectiveness and health benefits of 23-valent pneumococcal polysaccharide vaccine (PPSV23), 13-valent pneumococcal conjunctive vaccine (PCV13), and PCV13-PPSV23 sequential vaccination strategies in preventing pneumonia and other pneumococcal diseases among the senior citizens (≥ 65 years) in China. The cost-effectiveness of pneumococcal vaccines compared to no vaccination was estimated using a decision-tree Markov model from a societal perspective. Parameters including epidemiological data, vaccine efficacy and cost data were obtained from previous studies. Cases and deaths averted, quality-adjusted life years (QALYs) gained, and incremental cost-effectiveness ratios (ICERs) were presented as outcomes. Sensitivity analyses were performed to explore the uncertainty in the model. In the base-case analysis, compared with no pneumococcal vaccination, the ICERs of PPSV23, PCV13 and PCV13-PPSV23 are US$10,776.7/QALY, $9,193.2/QALY, and $15,080.0/QALY, respectively. PCV13 is the most cost-effective strategy and the only cost-effective strategy based on a threshold of the one-time national GDP per capita, whereas PPSV23 vaccine strategy is provided with the lowest cost, and PCV13-PPSV23 demonstrates the greatest impact on pneumococcal disease burden. Sensitivity analyses reveal that the results are greatly influenced by serotype coverage, vaccine efficacy, CAP incidence and vaccine prices. The PCV13 vaccination for Chinese seniors is more cost-effective than PPSV23 vaccination and PCV13-PPSV23 sequential vaccination.
引用
- Guo J, Zhang H, Zhang H, et al. Cost-effectiveness of pneumococcal vaccines among adults aged 65 years and older in China: A comparative study. Vaccine. 2022. PMID: 36522264. doi:10.1016/j.vaccine.2022.12.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。